Marker Therapeutics, Inc

(NASDAQ:MRKR)

Latest On Marker Therapeutics, Inc (MRKR):

Date/Time Type Description Signal Details
2023-05-31 22:47 ESTNewsMarker jumps 32% on pre-clinical data for T cell therapyN/A
2023-05-08 13:08 ESTNewsMarker Therapeutics gets new chief medical officerN/A
2023-05-01 11:49 ESTNewsMarker stock rises after plans to sell cell manufacturing assets to CellReady for ~$19MN/A
2023-03-22 14:13 ESTNewsMarker Therapeutics GAAP EPS of -$3.58 beats by $0.02, revenue of $9.01M beats by $0.01MN/A
2022-12-13 09:08 ESTNewsMarker Therapeutics to raise funds via $25M share saleN/A
2022-11-10 20:13 ESTNewsMarker Therapeutics GAAP EPS of -$0.08, revenue of $3.9MN/A
2022-09-13 14:34 ESTNewsMarker Therapeutics awarded $2M FDA grant for leukemia candidateN/A
2022-08-12 05:21 ESTNewsMarker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71MN/A
2022-05-13 21:50 ESTNewsMarker Therapeutics GAAP EPS of -$0.12 beats by $0.01, revenue of $964.32MN/A
2022-04-26 15:36 ESTNewsMarker Therapeutics inks contract with Wilson Wolf to manufacture cell therapiesN/A
2022-03-19 01:50 ESTNewsMarker Therapeutics GAAP EPS of -$0.55 beats by $0.02, revenue of $1.24MN/A
2021-10-22 15:50 ESTNewsMarker Therapeutics: Passing Through A Catalyst DesertN/A
2021-10-13 05:04 ESTNewsWarning: MRKR is at high risk of performing badlyN/A
2021-10-06 13:15 ESTNewsMRKR is at high risk of performing badlyN/A
2021-09-27 22:04 ESTNewsWarning: MRKR has been downgraded to Very BearishN/A
2021-09-23 07:54 ESTNewsWarning: MRKR has been downgraded to Very Bearish.N/A
2021-08-20 07:04 ESTNewsMarker shares surge 25% on $13M research award to support development of MT-401N/A
2021-08-11 04:44 ESTNewsMarker Therapeutics EPS misses by $0.01N/A
2021-07-29 01:44 ESTNewsMarker Therapeutics opens new cGMP manufacturing facility in HoustonN/A
2021-07-21 15:58 ESTNewsMarker Therapeutics completes safety lead-in portion of mid-stage leukemia studyN/A
2021-04-25 08:22 ESTNewsMarker Therapeutics Gets A 'Thumbs Up'N/A
2021-04-23 17:20 ESTNewsMarker Therapeutics: Undervalued Cancer Therapeutics With High PotentialN/A
2021-03-25 17:43 ESTNewsAstraZeneca’s updated data to address integrity issue; Vertex moves to focus list at Citi in today’s analyst actionN/A
2021-03-19 22:47 ESTNewsMarker Therapeutics surges as Cantor initiates with high PT and insider buying (updated)N/A
2021-03-13 04:13 ESTNewsMarker prices $50M underwritten public offeringN/A
2021-03-12 07:27 ESTNewsMarker Therapeutics under pressure on stock offeringN/A
2021-03-10 11:56 ESTEarnings EstimateAn EPS average of -$0.17 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-10 11:56 ESTFinancialsCompany financials have been released.Neutral
2021-03-10 11:56 ESTEarnings EstimateAn EPS average of -$0.61 is estimated for the 2022 year.Sell
2021-03-09 20:21 ESTNewsMarker Therapeutics EPS misses by $0.02, misses on revenueN/A
2021-02-10 15:15 ESTNewsHey Redditors, Redirect Your Attention To MarkerN/A
2021-01-13 16:22 ESTNewsMarker shares rise as it completes construction of its cGMP manufacturing facilityN/A
2021-01-06 16:13 ESTFinancialsCompany financials have been released.Neutral
2021-01-05 18:09 ESTNewsFDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapyN/A
2020-11-26 20:52 ESTFinancialsCompany financials have been released.Neutral
2020-11-25 12:39 ESTAnalyst RatingThe Analyst Target Price has decreased from $8 to $7.Neutral
2020-11-10 19:57 ESTNewsMarker Therapeutics EPS misses by $0.02N/A
2020-11-10 19:56 ESTNewsMarker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-10 12:36 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 12:36 ESTEarnings EstimateAn EPS average of -$0.15 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-07 16:31 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:26 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:32 ESTFinancialsCompany financials have been released.Neutral
2020-09-07 01:05 ESTAnalyst RatingThe Analyst Target Price has increased from $6.63 to $8.Buy
2020-08-14 09:30 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 13:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 05:20 ESTAnalyst RatingThe Analyst Target Price has decreased from $7.13 to $6.63.Neutral
2020-08-10 17:46 ESTNewsMarker Therapeutics EPS in-lineN/A
2020-08-06 21:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:43 ESTFinancialsCompany financials have been released.Neutral

About Marker Therapeutics, Inc (MRKR):

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

MRKR Quotes by TradingView

See Advanced Chart

General

  • Name Marker Therapeutics, Inc
  • Symbol MRKR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 44
  • Last Split Factor1:12
  • Last Split Date2016-09-16
  • Fiscal Year EndDecember
  • IPO Date2014-03-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.markertherapeutics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 170.96
  • Price/Book (Most Recent Quarter) 3.94
  • Enterprise Value Revenue 226.69
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.69
  • Next Year EPS Estimate -$0.65
  • Next Quarter EPS Estimate -$0.17
  • Operating Margin -6188%
  • Return on Assets -39%
  • Return on Equity -80%
  • Revenue 466785
  • Earnings Per Share -$4.17
  • Revenue Per Share $0.01
  • Gross Profit -18413966
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 149.09 million
  • Analyst Target Price $7
  • Book Value Per Share $0.54
View More

Share Statistics

  • Shares Outstanding 79.3 million
  • Shares Float 35.34 million
  • % Held by Insiders 2989%
  • % Held by Institutions 29.82%
  • Shares Short 3.25 million
  • Shares Short Prior Month 3.38 million
  • Short Ratio 5.24
  • Short % of Float 11%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 1.26
  • 52 Week High $3.38
  • 52 Week Low $1.32
  • 50 Day Moving Average 2.44
  • 200 Day Moving Average 1.83
View More

Dividends

  • Dividend Date 2016-09-16
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Marker Therapeutics, Inc (MRKR) Dividend Calendar:

MRKR's last dividend payment was made to shareholders on September 16, 2016.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Marker Therapeutics, Inc (MRKR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.18-$0.16-12.5%
2020-09-302020-11-09$N/A-$0.16-$0.15-10.34%
2020-06-302020-08-10$N/A-$0.14-$0.142.3%
2020-03-312020-05-11$N/A-$0.14-$0.11-30.23%
2019-12-312020-03-12$213194-$0.11-$0.1312.7%
2019-09-302019-11-12$N/A-$0.12-$0.139.09%
2019-06-302019-08-08$N/A-$0.12-$0.136.25%
2019-03-312019-05-10$N/A-$0.12-$0.1729.41%
2018-12-312019-03-15$N/A-$2.99-$0.20-1395%
2018-09-302018-11-13$-205994-$0.32-$0.4427.27%
2018-06-302018-08-09$205994-$0.41
2018-03-312018-05-15$N/A-$0.30-$0.5039.82%
2017-12-312018-03-23$N/A-$0.30-$0.5040%
2017-09-302017-11-14$N/A-$0.39
2017-06-302017-08-07$N/A-$0.22
2017-03-312017-05-05$N/A-$0.29
2016-12-312017-03-14$N/A-$0.19
2016-09-302016-11-04$N/A-$0.29
2016-06-302016-08-15$N/A$0.35
2016-03-312016-04-14$N/A-$0.81
2015-12-312016-03-02$N/A-$2.91
2015-09-302015-11-16$N/A$0.37
2015-06-302015-08-14$N/A-$6.60
2015-03-312015-05-15$N/A-$0.43
2014-12-312015-02-25$N/A-$0.44
2014-09-302014-11-19$N/A-$1.08-$1.3218.18%
2014-06-302014-08-18$N/A$0.60-$1.44141.67%
2014-03-312014-05-28$N/A-$51.44
2013-12-312013-12-31$N/A-$34.44
2013-09-302013-09-30$N/A-$9.16
2013-06-302013-06-30$N/A-$10.44
2013-03-312013-03-31$N/A-$16.00
2012-12-312012-12-31$N/A-$31.85
2012-09-302012-09-30$N/A-$12.60
2012-06-302012-06-30$N/A-$53.26
2012-03-312012-03-31$N/A-$13.69
2011-12-312011-12-31$N/A$9.11
2011-09-302011-09-30$N/A-$21.46
2011-06-302011-06-30$N/A-$10.40
2011-03-312011-03-31$N/A-$33.40
2010-12-312010-12-31$N/A-$30.49
2010-09-302010-09-30$N/A-$34.41
2010-06-302010-06-30$N/A-$39.09
2010-03-312010-03-31$N/A-$50.47
2009-12-312009-12-31$N/A-$180.00
2009-09-302009-09-30$N/A-$26.38
2009-06-302009-06-30$N/A$57.13
2009-03-312009-03-31$N/A-$224.81
2008-12-312008-12-31$N/A-$246.73
2008-09-302008-09-30$N/A-$133.00
2008-06-302008-06-30$N/A-$382.90
2008-03-312008-03-31$N/A-$345.58
2007-12-312007-12-31$N/A-$600.02
2007-09-302007-09-30$N/A-$282.41
2007-06-302007-06-30$N/A-$474.48
2007-03-312007-03-31$N/A-$1,076.00
2006-12-312006-12-31$N/A-$600.06
2006-09-302006-09-30$N/A-$432.42
2006-06-302006-06-30$N/A-$240.40
2006-03-312006-03-31$N/A-$376.20
2005-12-312005-12-31$N/A-$201.24
2005-09-302005-09-30$N/A-$320.51
2005-06-302005-06-30$N/A-$472.78
2005-03-312005-03-31$N/A-$29.53
2004-12-312004-12-31$N/A-$1,500.15
2004-09-302004-09-30$N/A-$596.08
2004-06-302004-06-30$N/A-$778.21
2004-03-312004-03-31$N/A-$1,034.12
2003-12-312003-12-31$N/A-$4,630.11
2003-09-302003-09-30$N/A-$1,723.34
2003-06-302003-06-30$N/A-$2,284.86
2003-03-312003-03-31$N/A-$1,615.30
2002-09-302002-09-30$N/A-$1,113.25
2002-06-302002-06-30$N/A-$12,606.76
2002-03-312002-03-31$N/A-$6,429.76
2001-09-302001-09-30-$2,269.43
2001-06-302001-06-30$3,842.40
2001-03-312001-03-31-$31,991.99
2000-09-302000-09-30-$32,887.83
2000-06-302000-06-30-$33,786.01
2000-03-312000-03-31-$31,605.87
1999-09-301999-09-30-$34,645.70

Marker Therapeutics, Inc (MRKR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 5.98 million N/A N/A 3.82 million N/A
Income Before Tax -8.51 million N/A N/A -6.49 million -5.08 million
Selling General Administrative 2.53 million N/A N/A 2.83 million 1.91 million
Gross Profit N/A N/A N/A N/A -3.45 million
Ebit -8.51 million N/A N/A -6.56 million -5.36 million
Operating Income -8.51 million N/A N/A -6.64 million -5.36 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A 213194
Cost of Revenue N/A N/A N/A N/A 3.66 million
Total Other Income Expense Net N/A N/A N/A 31000 282875
Net Income From Continuing Operations -8.51 million N/A N/A -6.49 million -5.08 million
Net Income Applicable to Common Shares -8.51 million -7.37 million -6.34 million N/A -5.08 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -99821 N/A N/A
Change to Liabilities 1.19 million 1.57 million N/A -1.1 million -87974
Total Cash Flow from Investing Activities -3.11 million -3.83 million N/A -12862 -56739
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 550000 N/A 753354
Change to Operating Activities 289019 -1.03 million N/A 353209 -1.44 million
Change in Cash N/A N/A -3.65 million -4.57 million -4.97 million
Total Cash from Operating Activities -4.24 million -4.3 million -4.1 million -4.56 million -5.66 million
Depreciation N/A N/A 82626 80755 76838
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 1.27 million 1.36 million N/A 1.19 million 1.25 million
Capital Expenditures N/A N/A 99821 12862 56739
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 18.27 million N/A N/A 3.39 million 2.27 million
Total Stockholder Equity 27.34 million N/A N/A 39.5 million 44.09 million
Other Current Liabilities 388792 N/A N/A 293 273680
Total Assets 45.61 million N/A N/A 42.89 million 46.36 million
Common Stock 50731 48025 46617 N/A 45728
Other Current Assets 2.06 million N/A N/A N/A N/A
Retained Earnings -356.24 million -347.73 million -340.36 million -334.02 million -327.53 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash 21.35 million N/A N/A 40.26 million 43.9 million
Total Current Liabilities 6.4 million 6.02 million N/A 3.16 million 1.99 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 6.79 million 18.25 million 13.76 million N/A 872702
Total Current Assets 24.41 million 30.32 million N/A 42 million 45.49 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 27.34 million 30.6 million 34.51 million N/A 44.09 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 6.01 million 5.75 million N/A 1.66 million 993000

Marker Therapeutics, Inc (MRKR) Chart:

Marker Therapeutics, Inc (MRKR) News:

Below you will find a list of latest news for Marker Therapeutics, Inc (MRKR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Marker Therapeutics, Inc (MRKR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Marker Therapeutics, Inc (MRKR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920078459/0001104659-20-078459-index.htm
2018-11-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1094038/000000000018035057/0000000000-18-035057-index.htm
2019-06-20UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1094038/000000000019010106/0000000000-19-010106-index.htm
2018-10-25SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000107261318000512/0001072613-18-000512-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1094038/000110465919062594/0001104659-19-062594-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465919062634/0001104659-19-062634-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920015276/0001104659-20-015276-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920027550/0001104659-20-027550-index.htm
2020-03-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1094038/000110465920028589/0001104659-20-028589-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1094038/000110465920032463/0001104659-20-032463-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920032531/0001104659-20-032531-index.htm
2020-04-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1094038/000110465920048175/0001104659-20-048175-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920053395/0001104659-20-053395-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1094038/000110465920059515/0001104659-20-059515-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920059559/0001104659-20-059559-index.htm
2020-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920064746/0001104659-20-064746-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920067357/0001104659-20-067357-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920068051/0001104659-20-068051-index.htm
2020-06-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1094038/000110465920072918/0001104659-20-072918-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920075877/0001104659-20-075877-index.htm
2020-06-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920078459/0001104659-20-078459-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1094038/000110465920092706/0001104659-20-092706-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000110465920092766/0001104659-20-092766-index.htm
2018-10-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054557/0001144204-18-054557-index.htm
2018-10-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054562/0001144204-18-054562-index.htm
2018-10-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054565/0001144204-18-054565-index.htm
2018-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054584/0001144204-18-054584-index.htm
2018-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054586/0001144204-18-054586-index.htm
2018-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054989/0001144204-18-054989-index.htm
2018-10-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054992/0001144204-18-054992-index.htm
2018-10-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054993/0001144204-18-054993-index.htm
2018-10-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418054994/0001144204-18-054994-index.htm
2018-10-298-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418055613/0001144204-18-055613-index.htm
2018-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418056154/0001144204-18-056154-index.htm
2018-10-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418056172/0001144204-18-056172-index.htm
2018-10-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1094038/000114420418056186/0001144204-18-056186-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1094038/000114420418059353/0001144204-18-059353-index.htm
2018-11-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1094038/000114420418059361/0001144204-18-059361-index.htm
2018-11-16424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1094038/000114420418060520/0001144204-18-060520-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418061604/0001144204-18-061604-index.htm
2018-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418061745/0001144204-18-061745-index.htm
2018-11-293Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418062320/0001144204-18-062320-index.htm
2018-11-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418062322/0001144204-18-062322-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418062867/0001144204-18-062867-index.htm
2018-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420418062948/0001144204-18-062948-index.htm
2018-12-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418066573/0001144204-18-066573-index.htm
2018-12-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418066575/0001144204-18-066575-index.htm
2018-12-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420418066584/0001144204-18-066584-index.htm
2019-01-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419000592/0001144204-19-000592-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419001768/0001144204-19-001768-index.htm
2019-01-29424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1094038/000114420419003213/0001144204-19-003213-index.htm
2019-02-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000114420419007747/0001144204-19-007747-index.htm
2019-02-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000114420419007755/0001144204-19-007755-index.htm
2019-02-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000114420419007762/0001144204-19-007762-index.htm
2019-02-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419008704/0001144204-19-008704-index.htm
2019-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419009717/0001144204-19-009717-index.htm
2019-03-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1094038/000114420419014350/0001144204-19-014350-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419016685/0001144204-19-016685-index.htm
2019-03-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1094038/000114420419016692/0001144204-19-016692-index.htm
2019-03-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1094038/000114420419016699/0001144204-19-016699-index.htm
2019-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419019976/0001144204-19-019976-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419024949/0001144204-19-024949-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1094038/000114420419025316/0001144204-19-025316-index.htm
2019-05-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419025325/0001144204-19-025325-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420419025602/0001144204-19-025602-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420419025605/0001144204-19-025605-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420419025607/0001144204-19-025607-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420419025608/0001144204-19-025608-index.htm
2019-05-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000114420419026544/0001144204-19-026544-index.htm
2019-06-14S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1094038/000114420419030986/0001144204-19-030986-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419031591/0001144204-19-031591-index.htm
2019-06-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1094038/000114420419031879/0001144204-19-031879-index.htm
2019-07-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419035118/0001144204-19-035118-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419035266/0001144204-19-035266-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419037903/0001144204-19-037903-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419038680/0001144204-19-038680-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1094038/000114420419038714/0001144204-19-038714-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419040272/0001144204-19-040272-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1094038/000114420419045766/0001144204-19-045766-index.htm
2018-10-19SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000119312518303199/0001193125-18-303199-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1094038/000119312519040985/0001193125-19-040985-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1094038/000119312520038347/0001193125-20-038347-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055562/0001209191-18-055562-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055563/0001209191-18-055563-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055564/0001209191-18-055564-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055566/0001209191-18-055566-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055567/0001209191-18-055567-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055568/0001209191-18-055568-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055569/0001209191-18-055569-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055570/0001209191-18-055570-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919118055571/0001209191-18-055571-index.htm
2019-08-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919119045148/0001209191-19-045148-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919119045152/0001209191-19-045152-index.htm
2019-08-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919119046149/0001209191-19-046149-index.htm
2019-08-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919119046625/0001209191-19-046625-index.htm
2019-08-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919119046630/0001209191-19-046630-index.htm
2020-03-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018515/0001209191-20-018515-index.htm
2020-03-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018519/0001209191-20-018519-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018524/0001209191-20-018524-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018528/0001209191-20-018528-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018531/0001209191-20-018531-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018534/0001209191-20-018534-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018535/0001209191-20-018535-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018539/0001209191-20-018539-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018543/0001209191-20-018543-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018548/0001209191-20-018548-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000120919120018556/0001209191-20-018556-index.htm
2019-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1094038/000121390019001621/0001213900-19-001621-index.htm
2018-11-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000140840818000021/0001408408-18-000021-index.htm
2020-02-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000140840820000008/0001408408-20-000008-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000140840820000011/0001408408-20-000011-index.htm
2020-06-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1094038/000140840820000027/0001408408-20-000027-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1094038/000140840820000029/0001408408-20-000029-index.htm
2018-11-16EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1094038/999999999518002918/9999999995-18-002918-index.htm
2019-06-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1094038/999999999519001442/9999999995-19-001442-index.htm
2019-04-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1094038/999999999719002227/9999999997-19-002227-index.htm

Marker Therapeutics, Inc (MRKR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Marker Therapeutics, Inc (MRKR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2989%
Institutional Ownership: 2982%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-08-14Peter L. HoangPresident and CEOBuy10,000.004.6246,200.00189,711.00https://www.sec.gov/Archives/edgar/data/1094038/000120919119046149/0001209191-19-046149-index.htm
2019-05-09David Laskow-PooleyDirectorBuy7,260.0025,543.00https://www.sec.gov/Archives/edgar/data/1094038/000114420419025605/0001144204-19-025605-index.htm
2019-05-09Frederick Gerald WassermanDirectorBuy7,260.0025,543.00https://www.sec.gov/Archives/edgar/data/1094038/000114420419025602/0001144204-19-025602-index.htm
2019-05-09John Robert WilsonDirectorBuy7,260.006,068,043.00https://www.sec.gov/Archives/edgar/data/1094038/000114420419025607/0001144204-19-025607-index.htm
2019-05-09Norman David EansorDirectorBuy7,260.007,260.00https://www.sec.gov/Archives/edgar/data/1094038/000114420419025608/0001144204-19-025608-index.htm